Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
暂无分享,去创建一个
Stefano Ferrero | Gaetano Rocco | Gerardo Botti | G. Botti | R. Franco | G. Liguori | N. Normanno | S. Bosari | E. La Mantia | A. Morabito | G. Rocco | Renato Franco | Nicola Normanno | G. Aquino | S. Ferrero | Silvano Bosari | Nicola Martucci | Alessandro Morabito | Giuseppina Liguori | Federica Zito Marino | Gabriella Aquino | Elvira La Mantia | Lorenzo Rosso | Gabriella Gaudioso | Nicla De Rosa | Marianna Scrima | Antonello La Rocca | L. Rosso | N. Martucci | G. Gaudioso | F. Marino | A. La Rocca | Nicla de Rosa | M. Scrima
[1] Yi-long Wu,et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression , 2010, Molecular Cancer.
[2] Akihiko Yoshizawa,et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.
[3] Y. Yatabe,et al. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. , 2008, Cancer research.
[4] Akihiko Yoshizawa,et al. A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors , 2010, The American journal of surgical pathology.
[5] H. Shim,et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. , 2011, Archives of pathology & laboratory medicine.
[6] G. Botti,et al. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment? , 2013, Expert review of anticancer therapy.
[7] M. Ladanyi,et al. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. , 2010, The Journal of molecular diagnostics : JMD.
[8] A. Nicholson,et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] Elisabeth Brambilla,et al. Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .
[10] W. Gerald,et al. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.
[11] Yang Zhang,et al. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma , 2014, Scientific Reports.
[12] T. Mitsudomi,et al. Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma , 2014, BioMed research international.
[13] G. Rossi,et al. Lung Cancer Histologic and Immunohistochemical Heterogeneity in the Era of Molecular Therapies: Analysis of 172 Consecutive Surgically Resected, Entirely Sampled Pulmonary Carcinomas , 2014, The American journal of surgical pathology.
[14] J. Sørensen,et al. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer , 2012, Cancer Chemotherapy and Pharmacology.
[15] W. Travis,et al. United States lung carcinoma incidence trends: Declining for most histologic types among males, increasing among females , 1996, Cancer.
[16] H. Sasaki,et al. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. , 2007, Lung cancer.
[17] H. Sasaki,et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. , 2006, Japanese journal of clinical oncology.
[18] J. Nevins,et al. Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies , 2010, Journal of Molecular Medicine.
[19] K. Matsuo,et al. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] W. Franklin,et al. Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.
[22] Masahiro Tsuboi,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] Tomayoshi Hayashi,et al. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. , 2013, Clinical lung cancer.
[24] Setsuo Hirohashi,et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995 .
[25] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[26] A. Ardizzoni,et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. , 2011, Lung cancer.
[27] N. Cherdyntseva,et al. Intratumor heterogeneity: Nature and biological significance , 2013, Biochemistry (Moscow).
[28] Y. Ishikawa,et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.
[29] Hoguen Kim,et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung , 2007, Cancer.
[30] D. Haber,et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Ladanyi,et al. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] Hiromasa Yamamoto,et al. Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] Ping Yang,et al. Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[35] Charles A Powell,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. , 2011, Proceedings of the American Thoracic Society.
[36] A. Nassar,et al. Intratumoral Heterogeneity of Immunohistochemical Marker Expression in Breast Carcinoma: A Tissue Microarray-based Study , 2010, Applied immunohistochemistry & molecular morphology : AIMM.
[37] T. Mok,et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. , 2012, The oncologist.